At CDMO Live 2025, Elisabeth Stampa (Medicines for Europe), Elena Barboni (Flamma) and Agneta Larhed (RegSmart Life Science) discussed how Europe’s stringent new regulations could reshape the continent’s pharmaceutical manufacturing landscape. Europe’s pharmaceutical manufacturing sector faces an unprecedented challenge as
The COVID-19 pandemic fundamentally changed pharmaceutical manufacturing approaches – demonstrating it’s possible to dramatically compress traditional timelines while maintaining quality standards. At CDMO Live 2025, Fabrice Le Garrec, founder of the OSICS network, shared lessons learned from his experience during
“When you’re building something at the edge of science, it’s crucial to start with the problem, not the solution. My team has created 15 pharma startups using this approach, and 14 are still alive.” – Kerstin Papenfuss, Director of Pharma
At CDMO Live 2025, a panel sponsored by Lifecore Biomedical brought together industry quality leaders to discuss how quality management can become a strategic enabler rather than a compliance burden. The panel featured Jackie Klecker (EVP Quality & Development Services,
“Risk is always a function of volatility. And I think everyone agrees that volatility in markets, also in the pharmaceutical industry with regards to tariffs, has actually increased,” explains David Schneider, CEO of Qualifyze, discussing the evolving landscape of supplier
“We invest to meet the needs of the customer. What’s driving these investments are really the customer partnerships that we’re building to make these happen,” explains Arul Ramadurai, Chief Commercial Officer at Axplora. Axplora, a global leader in API small
At CDMO Live 2025, a panel of digital manufacturing experts explored how pharma companies are transforming external manufacturing operations through digital integration. Sponsored by Aizon. The Digital Divide: Big Pharma vs Mid-Size Players The panellists painted a stark contrast in
“Know your supply chain. Make sure you have it well mapped. The biggest thing that we’ve seen coming out of COVID was investments in technology – that’s what’s helping manufacturers respond to the unexpected.” Ryan Kelly, Senior Director of Supply
“There are not that many European CDMOs with commercial expertise in cell therapy – who understand the regulatory requirements and production challenges when you have to manufacture large quantities on a regular basis. This is why we ended up with
“Nobody knows exactly what will happen, so making yourself anxious about unknowns doesn’t help. You must be prepared for multiple scenarios, ready and flexible to react quickly when changes do occur.” Maik Talarczyk, Director of PMO Office and Strategy in
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
